MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.
New non-human primate data projects a human half-life of up to 100 days, potentially enabling treatment with only ...
What is the ‘golden dose’ and what are the risks? Medical News Today asks four experts to weigh in on the trend of trying to ...
About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...
About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...
Affordability and access drive "gray," says Sabina Hemmi, founder of GLP Winner, a consumer watchdog. Some microdose the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback